{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:52:26Z","timestamp":1791373946204,"version":"4.3.1"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eururo.2026.09.014","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:13:38Z","timestamp":1791371618000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Bladder Cancer"],"prefix":"10.1016","author":[{"given":"Veronica","family":"Mollica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Rosellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6476-6871","authenticated-orcid":false,"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.09.014_b0005","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa2601486","article-title":"Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer","volume":"395","author":"Galsky","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.09.014_b0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.euo.2022.04.008","article-title":"Contemporary staging for muscle-invasive bladder cancer: accuracy and limitations","volume":"5","author":"Hensley","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.09.014_b0015","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.09.014_b0020","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.09.014_b0025","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.09.014_b0030","doi-asserted-by":"crossref","unstructured":"Aydogdu C, Bukavina L, Cheng L, et al. Histological subtypes and divergent differentiation of urothelial carcinoma: histology, genomics, and management implications. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2026.05.030.","DOI":"10.1016\/j.eururo.2026.05.030"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826024097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826024097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:13:40Z","timestamp":1791371620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826024097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":6,"alternative-id":["S0302283826024097"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.09.014","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}